FOXM1 and ovarian cancer: Here in this study, we tested the possibility of domatinostat, a class I-selective HDAC inhibitor in clinical and preclinical stages of development for the treatment of cancer, as an inhibitor of FOXM1 expression in ovarian cancer cells.